Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2004-3-24
pubmed:abstractText
Immunization with heat-shock protein (HSP) gp96 elicits protective immunity to the cancer or virus-infected cells from which it is derived. Low doses of gp96 generate immunity, while doses 10 times the immunizing dose do not. We show here that injection of high doses of gp96 generates CD4(+) T cells that down-regulate a variety of ongoing immune responses. Immunization with high doses of gp96 prevents myelin basic protein- or proteolipid protein-induced autoimmune encephalomyelitis in SJL mice and the onset of diabetes in non-obese diabetic mice. The suppression of immune response can be adoptively transferred with CD4(+) cells and does not partition with the CD25 phenotype. The immunomodulatory properties of gp96 (and possibly other HSP) may be used for antigen-specific activation or suppression of cellular immune responses. The latter may form the basis for novel immunotherapies for autoimmune diseases.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0953-8178
pubmed:author
pubmed:issnType
Print
pubmed:volume
16
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
615-24
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:15039392-Adoptive Transfer, pubmed-meshheading:15039392-Animals, pubmed-meshheading:15039392-Antigens, Neoplasm, pubmed-meshheading:15039392-CD4-Positive T-Lymphocytes, pubmed-meshheading:15039392-CD8-Positive T-Lymphocytes, pubmed-meshheading:15039392-Cell Transplantation, pubmed-meshheading:15039392-Diabetes Mellitus, Type 1, pubmed-meshheading:15039392-Encephalomyelitis, Autoimmune, Experimental, pubmed-meshheading:15039392-Female, pubmed-meshheading:15039392-Fibrosarcoma, pubmed-meshheading:15039392-Glycosuria, pubmed-meshheading:15039392-Immune Tolerance, pubmed-meshheading:15039392-Immunohistochemistry, pubmed-meshheading:15039392-Immunologic Factors, pubmed-meshheading:15039392-Immunotherapy, Active, pubmed-meshheading:15039392-Insulin, pubmed-meshheading:15039392-Lipopolysaccharides, pubmed-meshheading:15039392-Lymphocyte Subsets, pubmed-meshheading:15039392-Mice, pubmed-meshheading:15039392-Mice, Inbred BALB C, pubmed-meshheading:15039392-Mice, Inbred NOD, pubmed-meshheading:15039392-Myelin Basic Proteins, pubmed-meshheading:15039392-Myelin Proteolipid Protein, pubmed-meshheading:15039392-Pancreas, pubmed-meshheading:15039392-Paralysis, pubmed-meshheading:15039392-Peptide Fragments, pubmed-meshheading:15039392-Receptors, Interleukin-2, pubmed-meshheading:15039392-Spleen, pubmed-meshheading:15039392-Time Factors, pubmed-meshheading:15039392-Tumor Cells, Cultured, pubmed-meshheading:15039392-Vaccination
pubmed:year
2004
pubmed:articleTitle
Immune modulation with high-dose heat-shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis.
pubmed:affiliation
Center for Immunotherapy of Cancer and Infectious Diseases, University of Connecticut School of Medicine, Farmington, CT 06030-1601, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't